Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Boston Scientific Corp (BSX)

Boston Scientific Corp (BSX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 154,824,032
  • Shares Outstanding, K 1,479,446
  • Annual Sales, $ 16,747 M
  • Annual Income, $ 1,854 M
  • EBIT $ 3,715 M
  • EBITDA $ 5,370 M
  • 60-Month Beta 0.68
  • Price/Sales 9.12
  • Price/Cash Flow 28.27
  • Price/Book 6.80

Options Overview Details

View History
  • Implied Volatility 29.53% ( +0.22%)
  • Historical Volatility 17.14%
  • IV Percentile 86%
  • IV Rank 39.09%
  • IV High 52.68% on 04/04/25
  • IV Low 14.68% on 08/13/24
  • Put/Call Vol Ratio 1.23
  • Today's Volume 11,948
  • Volume Avg (30-Day) 9,101
  • Put/Call OI Ratio 0.78
  • Today's Open Interest 228,956
  • Open Int (30-Day) 213,745

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 0.72
  • Number of Estimates 11
  • High Estimate 0.73
  • Low Estimate 0.72
  • Prior Year 0.62
  • Growth Rate Est. (year over year) +16.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
100.90 +2.72%
on 06/23/25
107.53 -3.62%
on 06/30/25
+2.27 (+2.24%)
since 06/18/25
3-Month
92.70 +11.80%
on 04/21/25
107.53 -3.62%
on 06/30/25
+8.52 (+8.96%)
since 04/17/25
52-Week
71.88 +44.18%
on 08/05/24
107.53 -3.62%
on 06/30/25
+28.09 (+37.18%)
since 07/18/24

Most Recent Stories

More News
Molina to Report Q2 Earnings: Healthy Revenues, Weak Pulse on Earnings

Healthcare plan provider, Molina Healthcare, Inc. MOH, is set to report second-quarter 2025 results on July 23, 2025, after the closing bell. The Zacks Consensus Estimate for the to-be-reported quarter’s...

CVS : 61.96 (-2.12%)
BSX : 103.64 (-0.97%)
MOH : 182.98 (-10.41%)
COR : 292.87 (-0.51%)
Abbott Stock Falls in Pre-Market Despite Q2 Earnings and Sales Beat

Abbott Laboratories ABT reported second-quarter 2025 adjusted earnings per share (EPS) of $1.26, which beat the Zacks Consensus Estimate by 0.8%. The figure improved 10.5% from the prior-year quarter’s...

ABT : 123.67 (+2.62%)
BSX : 103.64 (-0.97%)
VEEV : 282.29 (+2.11%)
ISRG : 518.62 (+0.48%)
Elevance to Report Q2 Earnings: Will Rising Costs Pressure Profits?

Elevance Health, Inc. ELV is set to report its second-quarter 2025 results on July 17, 2025, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently...

CVS : 61.96 (-2.12%)
BSX : 103.64 (-0.97%)
SMMT : 26.20 (-5.18%)
ELV : 277.09 (-8.38%)
ABT's FreeStyle Libre 3 Plus Now Available in Canada: Stock to Rise?

Abbott Laboratories ABT recently made its FreeStyle Libre 3 Plus sensor available to Canadians living with diabetes. This latest generation glucose monitoring device features the world's smallest glucose...

ABT : 123.67 (+2.62%)
BSX : 103.64 (-0.97%)
COR : 292.87 (-0.51%)
ALGN : 190.77 (-0.78%)
Is it Worth Adding Boston Scientific Stock to Your Portfolio Now?

Boston Scientific’s BSX robust MedSurg segment, driven by endoscopy, neuromodulation and urology businesses, is poised for further growth in the upcoming quarters. The long-term prospects of the WATCHMAN...

ABT : 123.67 (+2.62%)
BSX : 103.64 (-0.97%)
COR : 292.87 (-0.51%)
ALGN : 190.77 (-0.78%)
How Unusual Options Standout Boston Scientific (BSX) is Signaling a Statistical Edge

BSX stock may extend its solid performance as options activity and historical patterns suggest a bullish setup with favorable short-term odds.

BSX : 103.64 (-0.97%)
Will J&J's Q2 Results Reflect End of MedTech Issues & Higher Sales?

Johnson & Johnson's JNJ medical devices segment, known as MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment accounts for around 36% of J&J’s...

SYK : 389.40 (+0.13%)
BSX : 103.64 (-0.97%)
JNJ : 163.70 (+0.44%)
MDT : 89.61 (+0.09%)
What to Expect From Boston Scientific's Next Quarterly Earnings Report

Boston Scientific is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings growth.

ABT : 123.67 (+2.62%)
XLV : 131.84 (-0.66%)
BSX : 103.64 (-0.97%)
$SPX : 6,296.79 (-0.01%)
J&J's MedTech Segment Slowing Down: Will its Sales Recover in 2025?

Johnson & Johnson JNJ is one of the few large drug and medical device companies with a presence in both the pharmaceuticals as well as medical devices segments. J&J’s medical devices segment, called...

SYK : 389.40 (+0.13%)
BSX : 103.64 (-0.97%)
JNJ : 163.70 (+0.44%)
MDT : 89.61 (+0.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and...

See More

Key Turning Points

3rd Resistance Point 108.41
2nd Resistance Point 106.91
1st Resistance Point 105.27
Last Price 103.64
1st Support Level 102.13
2nd Support Level 100.63
3rd Support Level 98.99

See More

52-Week High 107.53
Last Price 103.64
Fibonacci 61.8% 93.91
Fibonacci 50% 89.71
Fibonacci 38.2% 85.50
52-Week Low 71.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar